Kornimate/medical-research-clean huggingface dataset:
a randomized controlled trial to promote physician-patient discussion of prostate cancer screening

Conditions: Prostate Cancer

Summary: prostate cancer is the most common type of cancer among men. it is also the second leading cause of cancer-related death among men. two screening tests are available to try to detect prostate cancer early - the digital rectal examination (dre) and the prostate specific antigen (psa) blood test. unfortunately, physicians aren't sure whether or not these two screening tests help save lives, and there's a lot of controversy about how to use them. recently, a major government committee (the u.s. preventive services task force) recommended that physicians discuss the risks and potential benefits of prostate cancer screening with their patients, and allow patients to make their own decision. because of the controversies, many physicians currently don't discuss prostate cancer with their patients. the problem is that it takes time and effort to have these discussions, and the information is complicated. a lot of patients have trouble understanding it, especially if they have a limited educational background or trouble reading. when patients have difficulty obtaining, understanding, and acting on basic health information, we say that they have "low health literacy." other researchers have shown that patients with low health literacy don't know as much about cancer screening and are less likely to get screened for various cancers. they also tend to be timid about discussing things with their doctor, and often go along with what the doctor says, rather than taking an active role in the decision making. in 2003, under irb approval, we conducted a study with 2 goals: 1) to encourage patients to talk to their doctor about prostate cancer screening, and 2) to learn more about the impact of low health literacy on these conversations. to promote conversation, we used two handouts, given to patients in the waiting room before they saw the doctor. the first was a patient education handout about prostate cancer screening, written in very simple terms with useful illustrations. the second was a handout that simply encouraged patients to talk to their doctor about prostate cancer. patients got one of the two handouts, or a nutritional handout that served as a control. after they saw their doctor, a research assistant briefly interviewed the patient to find out whether or not prostate cancer screening was discussed. we also measured the patients' health literacy skills, and asked a few other questions about their decision to get screened for prostate cancer.


Eligibility criteria:
inclusion criteria: * male * age 45-70 exclusion criteria: * unable to communicate in english * too ill * in police custody * visual acuity worse than 20/60 * history of prostate cancer * lack of cooperation * overt psychiatric illnesses

Keywords: health literacy physician-patient relationship prostate cancer
the impact of polycystic ovary syndrome (pcos) on quality of life and healthcare beliefs

Conditions: Polycystic Ovary Syndrome

Summary: women with polycystic ovary syndrome (pcos) between the age of 18 and 55 are being recruited to participate in an online survey to determine the impact of pcos on quality of life and interaction with the healthcare system. this online survey will take 15-20 minutes to complete. participants will receive no direct benefit, but the information provided will contribute to the knowledge of this condition and the development of improved healthcare for women with pcos. for more information or to participate in this study, please visit http://pcossurvey.vze.com


Eligibility criteria:
inclusion criteria: * women with polycystic ovary syndrome (pcos) between the age of 18 and 55 exclusion criteria: * n/a

Keywords: pcos polycystic ovary syndrome polycystic ovarian syndrome infertility ovulation
an open label prostate cancer study in japanese patients

Conditions: Prostate Cancer

Summary: the primary aim of study is to gain an initial assessment of safety and tolerability of azd3514 in japanese patients together with assessing pharmacokinetics (pk) and gaining a preliminary assessment of anti-tumour action. in this study, azd3514 will be administered to japanese patients with metastatic castration resistant prostate cancer.


Eligibility criteria:
inclusion criteria: * males aged 20 years or older. * histologically or cytologically proven diagnosis of prostate cancer for which no standard therapy is currently considered appropriate * documented evidence of metastatic prostate cancer * serum testosterone concentration ≤50 ng/dl * world health organisation (who) performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks exclusion criteria: * history of hypersensitivity to active or inactive excipients of azd3514 or drugs with a similar chemical structure or class to azd3514 * refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of azd3514 * inadequate bone marrow reserve or organ function * concurrent or recent treatment with certain medications or medical procedures * any medically important factors identified from electrocardiogram (ecg) measurements

Keywords: phase 1 metastatic castration resistant prostate cancer androgen receptor down regulation japanese
discovery asia - crestor in type iia and iib hypercholesteremia

Conditions: Hypercholesterolemia

Summary: this clinical trial is being performed to investigate the effect of 12 weeks treatment with rosuvastatin and atorvastatin in bringing subjects to their established eas ldl-c target goal.


Eligibility criteria:
inclusion criteria: * visit 1: 1. written informed consent to participate in the trial (appendix b) 2. male or female subjects, age \> 18 years 3. primary hypercholesterolaemia with cv risk \> 20%/10yrs, type 2 diabetes, a history of chd or other established atherosclerotic disease (definition given in appendix l). 4. subjects may be lipid-lowering therapy-naïve, but have completed 6-weeks dietary counselling before this visit or subjects may be treated with the 'start' dose of other lipid lowering therapy, which is ineffective, ie. the subject has not met ldl-c treatment goals. 5. subjects willing to follow all study procedures including attendance at clinics for scheduled study visits, fasting prior to blood draws and compliance with study treatment regimen visit 2: 6. subjects switched from start dose of a lipid lowering therapy (commonly accepted start dose) will have fasting ldl-c levels \> 3.1 mmol (120 mg/dl) 7. newly treated subjects, after a six-weeks dietary counselling, will have fasting ldl-c levels \> 3.5 mmol/l (135 mg/dl) 8. fasting triglycerides £ 4.52 mmol/l (400 mg/dl) 9. switched patients must stop current lipid lowering treatment at randomisation (visit 2) exclusion criteria: 1. known heterozygous or homozygous familial hypercholesterolaemia or known type iii hyperlipoproteinaemia (familial dysbetalipoproteinaemia) 2. documented secondary hypercholesterolaemia of any cause other than named in inclusion criteria 3 3. history of serious adverse effect or hypersensitivity reactions to other hmg-coa reductase inhibitors, in particular any history of myopathy 4. unstable angina within three months prior to inclusion in the study 5. active liver disease or hepatic dysfunction as defined by elevations of ast or alt ³ 1.5 times the uln. in this case, a second determination of hepatic tests will be performed after one week. if the dysfunction is confirmed, the subject must not be included in the study 6. known uncontrolled diabetes 7. uncontrolled hypertension defined as either resting diastolic blood pressure of \> 95mmhg or resting systolic blood pressure of \> 200 mmhg 8. unexplained serum ck \> 3 times uln (eg not due to recent trauma, intramuscular injections, heavy exercise etc) 9. serum creatinine \> 220 µmol/l (2.5mg/dl)
treating depression with transcranial direct current stimulation (tdcs)

Conditions: Depression

Summary: the purpose of this study is to see if transcranial direct current stimulation may improve the symptoms of depression.

the purpose of this study is to learn about a brain stimulating procedure called transcranial direct current stimulation (tdcs). in tdcs therapy, two moistened sponges are applied to the forehead while a small amount of electric current flows between them. these electrodes are placed on the head so that the electricity will pass through a region in the brain that is believed to contribute to depression. this study is intended to test the theory that the electromagnetic field created by the current may affect this region of the brain in a way that may improve the symptoms of depression. this may affect brain activity and function.

Eligibility criteria:
inclusion criteria: * has a diagnosis of a major depressive episode or bipolar disorder and is currently in a major depressive episode (without psychotic features) * total pretreatment hdrs (hamilton depression rating scale)-24 score \>= 18 (the hamilton depression rating scale is an interviewer scored tool for assessing the severity of depressive symtoms. the scale ranges from 0 (no symptoms, absence of depression) to 64 category ham-24 score normal, not depressed 9 or less mildly depressed 10 to 19 moderately depressed 20 to 29 markedly/severely depressed 30 or more) * capable and willing to provide informed consent exclusion criteria: * history of depression previously untreated with medication, bipolar disorder, schizophrenia, schizoaffective disorder (non mood disorder), psychosis, depression secondary to a medical condition, mental retardation, substance dependence or abuse within the past year (except nicotine), psychotic features in this or previous episodes, amnestic disorder, dementia or mms\<24, delirium * significant current history of autoimmune, endocrine, viral or vascular disorder affecting the brain * history of unstable cardiac disease, uncontrolled hypertension, or sleep apnea * changes in psychotropic medications within two weeks prior to study entry or patient is unable to maintain stable doses throughout the study trial * subject has an active suicidal plan and/or attempted suicide in the past twelve months * patients with a cgi of 6 or greater * subject is pregnant or has a positive pregnancy serum test

Keywords: depression transcranial direct current stimulation direct current stimulation tdcs
phase 3 extension study of dexpramipexole in als

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of the study is to collect long-term safety data from subjects with amyotrophic lateral sclerosis (als) exposed to dexpramipexole.

amyotrophic lateral sclerosis (als) is a rapidly progressive, degenerative disease of motor neurons in the brain and spinal cord that leads to muscle atrophy and spasticity in limb and bulbar muscles resulting in weakness and loss of ambulation, oropharyngeal dysfunction, weight loss, and ultimately respiratory failure. the purpose of this study is to collect long-term safety data from subjects with amyotrophic lateral sclerosis (als) exposed to dexpramipexole.

Eligibility criteria:
inclusion criteria: * subject has the ability to understand the purpose and risks of the study and provide signed and dated informed consent (or have the consent confirmed by a witness if unable to write) and authorization to use protected health information (phi) in accordance with national and local subject privacy regulations. * subject was enrolled in either cl211 (nct00931944) or study 223as302 (ncto1281189). * subject has completed their last visit in study cl211 (nct00931944) or study 223as302 (ncto1281189). * subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 1 month (females) or 3 months (males) after their last dose of study treatment. exclusion criteria: * subject withdrew prematurely from study cl211 (nct00931944) or study 223as302 (ncto1281189). * subject permanently discontinued study treatment in study cl211 (nct00931944) or study 223as302 (ncto1281189) for any reason other than enrollment into this study. * subject from study cl211 (nct00931944) or study 223as302 (ncto1281189) has a significant change in medical history (including laboratory tests or a clinically significant condition) that in the opinion of the investigator would impair the subject's medical fitness for participation and preclude treatment. * female subject who is pregnant or breastfeeding. * subject is currently enrolled in any investigational drug study other than study cl211 (nct00931944) or study 223as302 (ncto1281189). * subject is taking pramipexole, other dopamine agonists, any other agent with dopaminergic activity, or any other disallowed concomitant medication. * subject is unwilling or unable to comply with the requirements of the protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol. at a minimum, subjects who are not able to travel to the study site must be willing to agree to remote blood draws for clinical laboratory evaluations and telephone visits to report adverse events, concomitant medications, and amyotrophic lateral sclerosis functional rating scale (revised) (alsfrs-r) scores.

Keywords: als, motor neuron disease, amyotrophic lateral sclerosis
factors for predicting severe asthma exacerbators in adult asthmatics: a real word- effectiveness study

Conditions: Asthma

Summary: this study is a single-center, retrospective, cross-sectional study. it plan to investigate the predictors for asthma exacerbation in long term follow up real world management with analyzing big data of electronic medical records (emr).

the long-term goals of asthma treatment are to achieve well control of symptoms and to minimize the future risk of asthma exacerbations (aes). asthma is a heterogeneous disease with various responses to treatment and clinical outcomes. aes are a prominent feature of severe asthmatics; however, frequent aes have also been reported in mild asthmatics. this is a prospectively designed observational study to identify predictors for patients with frequent aes among adult asthmatics by analyzing medical big data of electronic medical records (emr), which will provide an insight in the long-term management of adult asthmatics in real-world practice.

Eligibility criteria:
inclusion criteria: * aged ≥17 years * patients having bronchial asthma with j45-j46 code of international classification of diseases (10th edition on emr) * asthmatics who had been treated by allergy or respiratory specialists exclusion criteria: * patients who has less than one year for asthma treatment
innovative device for pain management by millimeter band radiation: electronic-pain killer

Conditions: Aortic Valve Replacement

Summary: the objective of this study is to evaluate a new medical device in the management of pain. the principle of this new treatment is based on the emission of electromagnetic radiation in millimeter band. this new modality of pain management is evaluated in a perioperative management in patients undergoing surgery for aortic valve replacement. the hypothesis is that the use of this medical device in perioperative would reduce the consumption of postoperative morphine with an identical quality of analgesia. the decline in morphine consumption would allow a decrease in opioid adverse effects.


Eligibility criteria:
inclusion criteria: * candidate for an aortic valve replacement with extra-corporal flow. * wrist size between 14.5 and 18.5 centimeters (for the experimental group) * patient affiliated to social security * signature of the informed consent (for the experimental group) exclusion criteria for the control group : * patient with diabetes * patient with an evolutive cancer * patient with cardiac assistance * patient under the influence of opioid in the 48 hours before the surgery * patient deprived of liberty by judicial or administrative decision * patient subject to legal protection or unable to express his consent (guardianship or curators) exclusion criteria for the experimental group : * patient with diabetes * patient with an evolutive cancer * patient with surgery planning within 48 hours * patient with cardiac assistance * patient under the influence of opioid in the 48 hours before the surgery * patient suffering from a dermatological disease such as oozing dermatitis, hyper sweating, or an unhealed lesion in the wrists. * patient who has a piercing in the wrist or another metal material * patient known for having a multi-resistant bacterial strain * protected person referred to in articles l1121-5 to l1121-8 of the code of public health * exclusion period of another interventional study

Keywords: pain treatment intensive care cardiology medical device
patient-reported and clinical outcomes in adults with relapsed or refractory hodgkin's lymphoma receiving brentuximab vedotin

Conditions: Relapsed or Refractory Hodgkin's Lymphoma

Summary: the goal of this is study is focusing on assessment of patient-reported outcomes in terms of quality of life (qol) and symptom profile as well on evaluation of clinical efficacy and safety of bv in patients with refractory/resistant hl in a real-world setting.

information on qol in patients with refractory/relapsed hl treated with bv is quite limited till now. moreover, pro data in patients treated for refractory/relapsed hl with bv, including long-term effects of bv on patient's qol in a real-world setting are lacking. the goal of this is study is focusing on assessment of patient-reported outcomes in terms of qol and symptom profileas well on evaluation of clinical efficacy and safety of bv in patients with refractory/resistant hl in a real-world setting. for pros assessment qol and symptom data will be received from patients' reports before and at 3, 6, 9, 12 months after bv treatment start and in 3 months at follow-up (15 months after base-line). the maximum duration of pro monitoring - 15 months. to evaluate pros the followings tools will be used: rand sf-36 for quality of life assessment, edmonton symptom assessment system (esas-r) for symptom assessment and patient global impression of change (pgic) for assessment of a patient's belief about the effect of treatment. for evaluation of response rates, duration of response, pfs and for analysis of aes/saes during bv treatment the clinical data will be collected from health records at base-line, at 3, 6, 9, 12 months after bv treatment start and at 15 months of follow-up or till the last dose of bv. no randomization and stratification will be applied. the analysis of primary (pros assessment) and secondary outcomes (clinical outcomes) will be provided in the total patient population (n=70) and in two subgroups. the subgroups of interest will be: patients with relapsed or refractory hl who are not candidates for asct with prescribed treatment with bv as ≥2nd line therapy, and patients with relapse after asct with prescribed treatment with bv.

Eligibility criteria:
inclusion criteria: * adult patients with confirmed diagnosis of relapsed or refractory hl * at least 18 years of age at time of bv treatment decision * patients with relapsed or refractory hl who are not candidates for asct with prescribed treatment with bv as ≥2nd line therapy, and patients with relapse after asct with prescribed treatment with bv * patients with given informed consent * patients who are capable to fill out questionnaires * patients with expected life duration of at least 6 months exclusion criteria: * patients enrolled in clinical trials * patients with contraindications to bv in accordance with instruction for use
speckle tracking echocardiography analysis of left ventricular myocardium after percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy

Conditions: Hypertrophic Obstructive Cardiomyopathy

Summary: objective to investigate the left ventricular (lv) systolic function by speckle tracking echocardiography before and after percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy (hocm). percutaneous intramyocardial septal radiofrequency ablation (named liwen procedure) is a safe and effective treatment approach for hocm and results in sustained improvement in exercise capacity and persistent in reducing left ventricle outflow tract (lvot) gradient. however, the systolic function of the myocardial after liwen procedure in hocm patients is not well exploration and research. strain evaluation using speckle tracking echocardiography is an excellent tool for assessing regional and global lv functions. in this study, the investigators aimed to characterize regional and global strain using speckle tracking echocardiography to assess lv radial, circumferential and longitudinal systolic myocardial function in patients with hocm before and after liwen procedure.


Eligibility criteria:
inclusion criteria: 1. patients with symptoms that limit daily activities (new york heart association functional class \>ii, exercise-induced syncope) despite adequate medical treatment or when medical treatment is not tolerated 2. patients with a peak lvot gradient≥50 mm hg exclusion criteria: 1. those with a peak instantaneous doppler lvot gradient of \<50 mm hg 2. those with an indication for septal reduction therapy and other lesions requiring surgical intervention (e.g., mitral valve repair/replacement and papillary muscle intervention) 3. those with end-stage heart failure；and those the echocardialology image quality is not clear enough for strain analysis.

Keywords: cardiomyopathy, hypertrophic speckle tracking echocardiography